Stay up to date on research and information
Sign Up for FORCE NewslettersCancer Treatment for People with Inherited Mutations
Inherited mutations may affect treatment options or eligibility for clinical trials studying which treatments work best.
If you have an inherited mutation, have been diagnosed with cancer and any of the situations below apply to you, you may wish to speak to your doctor about your medical options.
- You have prostate cancer
- You have advanced ovarian cancer
- You have advanced cancer with no standard treatment options
Regardless of cancer type, people with a mutation may benefit from testing and may qualify for clinical trials looking for more effective treatments for cancer.
Targeted therapies for advanced cancers
PARP inhibitors are a type of that work by blocking a protein used to repair damaged . People with a mutation who have been diagnosed with cancer may want to ask their doctor about whether they might benefit from a clinical trial or treatment with a .
PARP inhibitors for prostate cancer
The , Lynparza () has received FDA-approval to treat men with , castration-resistent cancer, who have a mutation in or another gene linked to a certain type of damage repair. Lynparza may be used to treat men whose cancer has progressed on (Xtandi) or (Zytiga).
PARP inhibitors for advanced ovarian, or primary peritoneal cancer
Several PARP inhibitors have been approved to treat ovarian cancers at different stages of the disease. In some situations, a tumor known as an test ("hemologous recombination deficiency") can help women with an inherited mutation and advanced ovarian cancer learn if they may benefit from a .
after treatment
- testing can help women with advanced ovarian cancer learn if they may benefit from the Lynparza in combination with bevacizumab as after platinum chemotherapy.
- is approved for in women with advanced ovarian, , or primary peritoneal cancer who had a complete or partial response to platinum-based chemotherapy. for does not require an test.
after treatment of recurrent cancer
- , () and Lynparza are all approved for maintenance therapy in women with recurrent epithelial ovarian, , or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy. In this setting, none of these drugs requires an test.
PARP inhibitors or other targeted therapies for advanced cancers with no other treatment options
If you have a mutation and advanced cancer that no longer responds to standard therapy, you may have additional options. Talk with your doctor about tumor testing to learn whether you might benefit from a , another or participation in a clinical trial.
More Resources
Participate in Cancer Treatment Research
Below are some of our featured research studies looking at new treatments for people with mutations. To search for more studies, visit our Search and Enroll Tool.
